Movement Alert|Novanta falls 5.38% in Regular Trading, cautious guidance after earnings continues to weigh on shares

Market Focus11-12

On November 12, Novanta fell 5.38% in Regular Trading, trading at $115.95, with turnover of $7.9409 million.

The move followed continued market pressure after the company reported quarterly results above expectations but issued softer near-term guidance, keeping attention on the pace of profit conversion after the Riverpoint Medical acquisition.

For the latest reported quarter, adjusted EPS was $1.05 and revenue was $305.0 million, above consensus estimates of $0.97 and $301.0 million, respectively, while revenue rose 23% year over year, including about $32.9 million from Riverpoint Medical. However, Novanta guided fourth-quarter adjusted EPS to $0.91 to $0.96 versus market expectations of $1.02, and narrowed full-year adjusted EPS to $3.66 to $3.71 from $3.68 to $3.74 previously, while full-year revenue guidance was set at $1.135 billion to $1.140 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment